The global gastritis treatment market is estimated to be valued at US$ 131.76 billion in 2024 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030. Gastritis refers to the inflammation or irritation of the stomach lining. It can occur due to numerous reasons such as infection by Helicobacter pylori bacteria, intake of certain medications like NSAIDs, and heavy alcohol consumption. Gastric disorders like acidity, ulcers, and gastric erosion can develop if gastritis remains untreated for a prolonged period.
The global gastritis treatment market is driven by the rising prevalence of gastric disorders due to changing lifestyle habits and food preferences. According to studies, approximately 60-80% of the global population is infected by H. pylori bacteria, which is a major causative factor for gastritis. Furthermore, the market is also witnessing growth due to the increasing usage of over-the-counter antacids and proton pump inhibitors (PPIs) for instant relief from minor gastric problems.
Key Takeaways
Key players operating in the gastritis treatment market are Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Novartis AG, Takeda Pharmaceutical Company Limited. These players collectively account for a significant share of the global market.
The rising prevalence of gastric disorders like acidity and ulcers is fueling the demand for gastritis treatment drugs. According to estimates, nearly 25% of the adult population suffers from acidity or heartburn issues globally.
Technological advancements are being made in drug delivery systems and formulations for gastritis treatment. Many players are introducing novel drug combinations, controlled-release formulations, and other innovations to enhance drug efficacy.
Market Trends
Increased adoption of combination therapy - Many clinical trials are exploring the efficacy of combining multiple drugs like PPIs with antibiotics for achieving faster and better relief from chronic gastritis caused by H. pylori infections. This trend is expected to continue over the forecast period.
Rise in natural and herbal treatment options - With growing preference for natural remedies, herbal formulations containing ingredients like licorice, slippery elm, and marshmallow are gaining attention for treating minor gastric disorders like acidity.
Market Opportunities
Emerging markets in Asia Pacific and Latin America - These regions are expected to offer lucrative opportunities for gastritis treatment market players owing to increasing healthcare expenditure, growing patient awareness, and rising economic prowess.
Focus on pediatric gastritis treatment - Developing safer and more effective drugs for treating gastritis in children can open new growth avenues as gastric issues are also prevalent among the pediatric population.
Impact of COVID-19 on Gastritis Treatment Market Growth
The COVID-19 pandemic significantly impacted the gastritis treatment market. During the initial stages of the outbreak, regular medical appointments and procedures declined as patients delayed or postponed non-critical care to avoid hospitals and clinics. This moderately affected the demand for gastritis treatment drugs in 2020. However, as the pandemic progressed, physicians started remote consultations and telehealth services to continue monitoring patients with chronic conditions like gastritis.
With lockdowns and restrictions imposed worldwide, mental health issues increased substantially. Stress, depression and anxiety are prominent risk factors for gastritis flares. Consequently, stress-related gastritis cases rose owing to pandemic-related worries. This drove greater reliance on over-the-counter antacids and proton pump inhibitors for symptomatic relief. Overall medicine sales volume recovered in 2021 as healthcare facilities resumed normal operations with strict safety protocols.
Going forward, the gastritis treatment market is expected to grow steadily. Drug makers are focusing on developing novel targeted therapies to strengthen treatment options. Telehealth can play a bigger role in long-term management of gastritis patients. Stress management programs may help curb pandemic-worsened gastrointestinal issues. Additionally, researchers are investigating the intestinal microbiome’s role in gastritis to identify new prevention and treatment avenues. However, future waves of the virus remain a challenge for this market.
Geographical Regions with Highest Value for the Gastritis Treatment Market
The gastritis treatment market in the United States accounts for the highest value, estimated at over US$ 35 billion in 2024. High healthcare spending per capita and easy availability of advanced drugs drive the large market size in the US. Another major revenue generator is Western Europe, where the market is projected to be worth around US$ 25 billion by 2024.
Major countries contributing to the European market are Germany, France, Italy and the UK. Higher disease prevalence due to sedentary lifestyle and aging population supports market growth. Availability of universal healthcare and reimbursement for gastritis medications boosts treatment uptake. Furthermore, Asia Pacific is emerging as the fastest growing regional market for gastritis treatment. Rapid economic development, growing medical infrastructure and large patient pools present lucrative opportunities.
Fastest Growing Regional Market for Gastritis Treatment
The Asia Pacific region holds tremendous potential and is poised to be the fastest growing regional market for gastritis treatment. Rising health awareness, expanding medical insurance coverage and increasing discretionary incomes are major drivers. Additionally, growing preference for Western diets high in processed foods and sugars is correlated with rising dyspepsia rates. Subsequently, the prevalence of chronic gastritis requiring long-term management is on the rise.
Countries like China, India and South Korea especially contribute to high market growth owing to their huge populations and improving healthcare access. Generic drug manufacturing capabilities in these nations also make treatment more affordable. Furthermore, foreign investments are augmenting pharmaceutical R&D. As a result, novel therapies and efficient diagnostics are being developed to address unmet needs. The emerging Asia Pacific market will witness a CAGR of around 8% between 2023-2030, outperforming global market expansion.
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/)
